<DOC>
	<DOCNO>NCT00837915</DOCNO>
	<brief_summary>The objective study compare single-dose relative bioavailability Ranbaxy Schering ( Claritin-D® 24 hour ) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets , fully replicate design , fast condition .</brief_summary>
	<brief_title>Bioequivalnce Study Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions</brief_title>
	<detailed_description>The study conduct open-label , randomize , Single-Dose , Fully replicate , 4-way Crossover Study compare single-dose relative bioavailability Ranbaxy Schering ( Claritin_D® 24 hour ) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets , Healthy adult Volunteers Under Fasting Conditions A total 40 subject ( 30 male 10 female ) include study , 36 ( 27 male 9 female ) finish study accord protocol .</detailed_description>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<criteria>Healthy adult male female volunteer , 1845 year age Weighing least 60 kg male 52 kg female within 15 % ideal weight ( Table `` Desirable Weights Adults '' , Metropolitan Life Insurance Company , 1983 ) ; Medically healthy subject clinically normal laboratory profile ; Females childbearing potential either sexually inactive ( abstinent ) 14 day prior study throughout study use one follow acceptable birth control method : surgically sterile ( bilateral tubal ligation , hysterectomy bilateral oophorectomy ) 6 month minimum IUD place least 3 month barrier method ( condom , diaphragm ) spermicide least 14 day prior start study .throughout study surgical sterilization partner ( vasectomy 6 month minimum hormonal contraceptive least 3 month prior start study Other birth control method may deem acceptable . Postmenopausal woman amenorrhea least 2 year eligible ; Voluntarily consent participate study . Subject candidate must enrol study meet follow criterion : History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . In addition , history presence : alcoholism drug abuse within past year hypersensitivity idiosyncratic reaction loratidine H1receptor antagonist hypersensitivity idiosyncratic reaction pseudoephederine sympatomimetic amine glaucoma hypermetropia Subjects receive monoamine oxidase ( MAO ) inhibitor within 14 day stop use MAO inhibitor , sympathomimetic amine . Subjects use drug substance know strong inhibitor CYP ( cytochrome P450 ) enzymes within 10 day study start . Subjects use drug substance know strong inducer CYP ( cytochrome P450 ) enzymes within 28 day study start . Female subject pregnant lactating . Subjects abnormal diet ( whatever reason ) 28 day prior first dose . Subjects , completition study , would donate excess : 500 mL blood 14 day , 500750 mL blood 14 day ( unless approve principal Investigator ) , 1000 mL blood 90 day , 1250 mL blood 120 day , 1500 mL blood 180 day , 2000 mL blood 270 day , 2500 mL blood 1 day , Subjects participate another clinical trial within 28 day prior study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Bioequivaelnce Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended Release Tablets</keyword>
</DOC>